Jacobs Levy Equity Management, Inc Cidara Therapeutics, Inc. Transaction History

Jacobs Levy Equity Management, Inc

  • $24.7 Billion
  • Q3 2024

Shares

17 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2021

Feb 14, 2022
SELL
$1.18 - $2.18 $701,751 - $1.3 Million
-594,705 Closed
0 $0
Q3 2021

Nov 15, 2021
BUY
$1.48 - $2.35 $227,394 - $361,065
153,645 Added 34.84%
594,705 $1.33 Million
Q2 2021

Aug 16, 2021
SELL
$1.87 - $2.7 $437,948 - $632,331
-234,197 Reduced 34.68%
441,060 $891,000
Q1 2021

May 17, 2021
BUY
$2.06 - $3.01 $782,070 - $1.14 Million
379,646 Added 128.43%
675,257 $1.8 Million
Q4 2020

Feb 16, 2021
BUY
$1.99 - $3.25 $588,265 - $960,735
295,611 New
295,611 $591,000
Q2 2020

Aug 17, 2020
SELL
$2.39 - $4.0 $209,196 - $350,120
-87,530 Closed
0 $0
Q1 2020

May 15, 2020
SELL
$1.74 - $4.26 $99,317 - $243,156
-57,079 Reduced 39.47%
87,530 $217,000
Q4 2019

Feb 14, 2020
BUY
$1.77 - $3.84 $255,957 - $555,298
144,609 New
144,609 $555,000
Q2 2019

Aug 13, 2019
SELL
$1.49 - $2.94 $143,014 - $282,190
-95,983 Closed
0 $0
Q1 2019

May 14, 2019
SELL
$2.35 - $3.27 $60,380 - $84,019
-25,694 Reduced 21.12%
95,983 $254,000
Q4 2018

Feb 14, 2019
BUY
$2.1 - $4.5 $6,090 - $13,050
2,900 Added 2.44%
121,677 $286,000
Q3 2018

Nov 14, 2018
BUY
$3.7 - $5.25 $126,170 - $179,025
34,100 Added 40.27%
118,777 $523,000
Q2 2018

Aug 14, 2018
SELL
$3.75 - $6.05 $72,671 - $117,242
-19,379 Reduced 18.62%
84,677 $440,000
Q1 2018

May 15, 2018
BUY
$4.0 - $8.15 $120,556 - $245,632
30,139 Added 40.77%
104,056 $416,000
Q4 2017

Feb 13, 2018
BUY
$6.35 - $8.75 $151,517 - $208,783
23,861 Added 47.67%
73,917 $503,000
Q3 2017

Nov 14, 2017
SELL
$5.75 - $8.1 $81,144 - $114,307
-14,112 Reduced 21.99%
50,056 $405,000
Q2 2017

Nov 09, 2017
BUY
N/A
64,168
64,168 $481,000

About Cidara Therapeutics, Inc.

CDTX Quotes by TradingView
  • Ticker CDTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 70,075,696
  • Market Cap $1.24B
  • Description
  • Cidara Therapeutics, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of long-acting anti-infectives for the treatment and prevention of infectious diseases and oncology in the United States. The company's lead product candidate is rezafungin acetate, a novel molecule in the echinocandin class of antifu...
More about CDTX
Track This Portfolio

Track Jacobs Levy Equity Management, Inc Portfolio

Follow Jacobs Levy Equity Management, Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jacobs Levy Equity Management, Inc, based on Form 13F filings with the SEC.

News

Stay updated on Jacobs Levy Equity Management, Inc with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email